Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
Source: SeekingAlpha
2026-05-06 07:30:08 ET
Alkermes Overview
When I last wrote about Alkermes ( ALKS ) in early January this year, the thesis was based on the clinical data from Vibrance-2 and the pending transaction with Avadel; Alkermes was transitioning away from being dependent upon royalties and manufacturing and toward becoming an integrated neuroscience company with real opportunities within sleep medicine. Four months later, it is even more clear. The Avadel acquisition has been completed, LUMRYZ is part of Alkermes' commercial product offerings, and alixorexton is in phase 3 development....
Read the full article on Seeking Alpha
For further details see:
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
Alkermes plc
NASDAQ: ALKS
ALKS Trading
-0.93% G/L:
$52.09 Last:
467,596 Volume:
$52.96 Open:
ALKS Latest News
June 17, 2026 04:15:00 pm
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 15, 2026 07:00:00 am
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 04, 2026 07:00:00 am
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 03, 2026 04:05:00 pm
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
$5,792,322,216
157,043,263
0.1%
131
N/A
Pharmaceuticals
Healthcare
IE
Dublin 4
